1. Within the proximal renal tubule, which transporter is responsible for the majority of filtered glucose reabsorption, and in which segment is it predominantly expressed?
A) SGLT-1, expressed predominantly in the late proximal tubule (S3 segment), reabsorbing roughly 90% of filtered glucose
B) GLUT2, expressed on the luminal membrane of the early proximal tubule, performing the bulk of glucose reabsorption
C) SGLT-2, expressed predominantly in the early proximal tubule (S1 and S2 segments), reabsorbing approximately 90% of filtered glucose
D) SGLT-1, expressed in the early proximal tubule (S1 segment), reabsorbing approximately 90% of filtered glucose as a high-capacity transporter
E) SGLT-2, expressed predominantly in the late proximal tubule (S3 segment), functioning as a low-capacity salvage transporter for the final 10% of filtered glucose
ANSWER: C
Rationale:
The kidney filters approximately 180 grams of glucose per day, nearly all reabsorbed in the proximal tubule. Sodium-glucose cotransporter 2 (SGLT-2) is expressed predominantly in the early proximal tubule (S1 and S2 segments) and, as a low-affinity but high-capacity transporter, mediates approximately 90% of renal glucose reabsorption. This is why SGLT-2 is the pharmacologic target for glycosuric glucose lowering.
Option A: Option A is incorrect because it assigns the dominant reabsorptive role to SGLT-1; SGLT-1 is a high-affinity, lower-capacity transporter in the S3 segment that handles only the residual ~10% as a salvage pathway when SGLT-2 is saturated.
Option B: Option B is incorrect because GLUT2 is the basolateral facilitated transporter that moves glucose out of the cell into the interstitium; it is not the luminal uptake transporter and does not perform luminal reabsorption.
Option D: Option D is incorrect because it misassigns the high-capacity 90% reabsorption to SGLT-1; that quantitative role belongs to SGLT-2, and SGLT-1 is not the early-segment high-capacity transporter.
Option E: Option E is incorrect because, although SGLT-2 is the correct transporter, it is expressed in the early (S1/S2) segments and is the high-capacity, dominant transporter, not a late-segment low-capacity salvage transporter.
2. A patient with long-standing type 2 diabetes mellitus and substantial beta-cell failure (low C-peptide) is started on an SGLT-2 inhibitor. Why does this drug class retain glucose-lowering efficacy even in patients with significant insulin deficiency?
A) Its glucose-lowering mechanism is insulin-independent, acting by blocking renal tubular glucose reabsorption and forcing urinary glucose excretion regardless of insulin secretion or action
B) It directly stimulates pancreatic beta-cell insulin secretion through closure of ATP-sensitive potassium channels, restoring postprandial insulin release
C) It enhances peripheral insulin sensitivity at skeletal muscle, allowing residual endogenous insulin to clear glucose far more effectively
D) It suppresses hepatic gluconeogenesis by activating AMP-activated protein kinase, an effect that does not require circulating insulin to lower glucose
E) It slows gastric emptying and augments glucagon-like peptide-1 release, blunting postprandial glucose excursions independent of beta-cell reserve
ANSWER: A
Rationale:
SGLT-2 inhibitors lower glucose by competitively blocking SGLT-2 at the luminal surface of the early proximal tubule, reducing glucose reabsorption and producing glycosuria of roughly 60 to 90 grams per day. Because glucose is eliminated in the urine rather than driven into cells, the mechanism does not depend on insulin secretion or insulin action and therefore retains efficacy across the spectrum of type 2 diabetes mellitus (T2DM), including in patients with significant insulin deficiency.
Option B: Option B is incorrect because it describes the sulfonylurea/meglitinide mechanism (ATP-sensitive potassium channel closure driving insulin secretion), which requires functioning beta cells and would lose efficacy with beta-cell failure.
Option C: Option C is incorrect because enhancement of peripheral insulin sensitivity describes thiazolidinedione action and still depends on available insulin to clear glucose; it is not the SGLT-2 inhibitor mechanism.
Option D: Option D is incorrect because AMP-activated protein kinase activation and suppression of hepatic gluconeogenesis describe metformin's proposed mechanism, not SGLT-2 inhibition.
Option E: Option E is incorrect because slowing gastric emptying and augmenting incretin signaling describe glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor actions, not the glycosuric renal mechanism of SGLT-2 inhibitors.
3. SGLT-2 inhibitors confer renoprotection in diabetic kidney disease through a hemodynamic effect on the glomerulus. Which mechanism best explains this intraglomerular pressure reduction?
A) Efferent arteriolar vasodilation produced by local bradykinin accumulation, which lowers intraglomerular pressure and reduces filtration fraction
B) Direct inhibition of the basolateral sodium-potassium ATPase in the proximal tubule, abolishing the sodium gradient that drives glomerular hyperfiltration
C) Systemic blood pressure reduction alone, which is transmitted directly to the glomerular capillary bed and accounts entirely for the fall in intraglomerular pressure
D) Reduced proximal sodium reabsorption increases sodium delivery to the macula densa, activating tubuloglomerular feedback that constricts the afferent arteriole and lowers intraglomerular pressure
E) Increased proximal sodium reabsorption decreases sodium delivery to the macula densa, which dilates the afferent arteriole and reduces glomerular filtration
ANSWER: D
Rationale:
In the proximal tubule, SGLT-2 cotransports sodium with glucose. Inhibiting SGLT-2 reduces proximal sodium reabsorption and thereby increases sodium delivery to the macula densa of the juxtaglomerular apparatus. This heightened distal sodium delivery activates tubuloglomerular feedback, producing afferent arteriolar vasoconstriction that lowers single-nephron glomerular filtration rate and reduces intraglomerular pressure, which underlies the renoprotective effect in diabetic kidney disease (DKD).
Option A: Option A is incorrect because it describes efferent dilation (the renin-angiotensin-aldosterone system blockade mechanism), whereas SGLT-2 inhibition acts on the afferent arteriole; the node and direction of vascular action are different.
Option B: Option B is incorrect because SGLT-2 inhibitors act competitively at the luminal SGLT-2 transporter, not by inhibiting the basolateral sodium-potassium ATPase, and this is not the mechanism of the glomerular pressure effect.
Option C: Option C is incorrect because, although SGLT-2 inhibitors modestly lower systemic blood pressure, the renoprotective intraglomerular effect is mediated specifically through tubuloglomerular feedback and afferent constriction, not explained entirely by systemic pressure transmission.
Option E: Option E is incorrect because it inverts the physiology: SGLT-2 inhibition increases (not decreases) macula densa sodium delivery and constricts (not dilates) the afferent arteriole.
4. The renoprotective hemodynamic effect of SGLT-2 inhibitors is often described as analogous to, but mechanistically distinct from, renin-angiotensin-aldosterone system (RAAS) blockade. Which statement correctly contrasts the two?
A) Both RAAS blockade and SGLT-2 inhibition lower intraglomerular pressure by constricting the afferent arteriole, making their renal hemodynamic actions essentially identical
B) RAAS blockade reduces intraglomerular pressure by dilating the efferent arteriole, whereas SGLT-2 inhibition reduces it by constricting the afferent arteriole; both lower intraglomerular hypertension but act on different nodes of the glomerular circuit
C) RAAS blockade constricts the afferent arteriole while SGLT-2 inhibition dilates the efferent arteriole, with both raising filtration fraction
D) RAAS blockade dilates the afferent arteriole and SGLT-2 inhibition dilates the efferent arteriole, so the two should never be combined because of additive hypofiltration
E) Both agents raise intraglomerular pressure to improve clearance, and their renoprotection derives from increased single-nephron glomerular filtration rate rather than pressure reduction
ANSWER: B
Rationale:
Both drug classes reduce intraglomerular hypertension, but they act on opposite arterioles. RAAS blockade preferentially dilates the efferent arteriole (reducing the post-glomerular resistance that drives intraglomerular pressure), whereas SGLT-2 inhibition, through tubuloglomerular feedback, constricts the afferent arteriole (reducing pre-glomerular inflow). Both lower intraglomerular pressure but at different nodes of the regulatory circuit, which is why their renoprotective effects can be complementary.
Option A: Option A is incorrect because it claims both act on the afferent arteriole and are identical; RAAS blockade acts chiefly on the efferent arteriole.
Option C: Option C is incorrect because it inverts both: RAAS blockade dilates the efferent (not constricts the afferent) and SGLT-2 inhibition constricts the afferent (not dilates the efferent), and both lower rather than raise filtration fraction in a way that protects the glomerulus.
Option D: Option D is incorrect because it misstates both mechanisms and the false claim that they cannot be combined; in practice they are used together for additive renoprotection.
Option E: Option E is incorrect because both agents lower, not raise, intraglomerular pressure, and renoprotection derives from reduced intraglomerular hypertension, not increased single-nephron filtration.
5. Among the approved SGLT-2 inhibitors, selectivity for SGLT-2 over SGLT-1 varies. Which statement correctly characterizes this selectivity across agents?
A) Canagliflozin is the most SGLT-2-selective agent, with negligible SGLT-1 activity at any dose, while empagliflozin has the greatest SGLT-1 cross-reactivity
B) All four agents have identical SGLT-2/SGLT-1 selectivity, so the choice among them is based solely on dosing frequency
C) Dapagliflozin is the only agent with meaningful intestinal SGLT-1 inhibition, which is responsible for its diarrhea risk relative to the rest of the class
D) Ertugliflozin has the lowest SGLT-2 selectivity of the class and derives most of its glycosuric effect from intestinal SGLT-1 blockade
E) Empagliflozin is the most SGLT-2-selective agent with negligible SGLT-1 activity, whereas canagliflozin has partial SGLT-1 inhibitory activity that is modest at 100 mg and more pronounced at the 300 mg dose
ANSWER: E
Rationale:
Empagliflozin is the most selective SGLT-2 inhibitor in the class, with negligible SGLT-1 activity, and dapagliflozin is likewise highly selective. Canagliflozin has lower SGLT-2 selectivity and exhibits partial SGLT-1 inhibitory activity that is modest at 100 mg and more pronounced at 300 mg, transiently reducing intestinal post-meal glucose absorption and augmenting its glycosuric effect.
Option A: Option A is incorrect because it reverses the relationship: canagliflozin (not empagliflozin) is the agent with SGLT-1 cross-reactivity, and empagliflozin is the most selective.
Option B: Option B is incorrect because the agents do not share identical selectivity; selectivity differs meaningfully, with canagliflozin being the notable lower-selectivity agent.
Option C: Option C is incorrect because dapagliflozin is highly SGLT-2 selective with minimal SGLT-1 activity; canagliflozin, not dapagliflozin, is the agent with appreciable SGLT-1 activity.
Option D: Option D is incorrect because ertugliflozin does not derive its effect chiefly from intestinal SGLT-1 blockade; the glycosuric mechanism across the class is renal SGLT-2 inhibition, and canagliflozin is the agent associated with SGLT-1 cross-activity.
6. A patient on an SGLT-2 inhibitor is started on a strong cytochrome P450 3A4 (CYP3A4) inhibitor for another condition. Based on the metabolic pathway of the SGLT-2 inhibitor class, what is the expected pharmacokinetic interaction?
A) Minimal CYP-mediated interaction is expected, because SGLT-2 inhibitors are metabolized primarily by glucuronidation (UGT enzymes) with only minimal cytochrome P450 involvement
B) A large increase in SGLT-2 inhibitor exposure is expected, because the class is metabolized predominantly by CYP3A4 and clearance will fall sharply
C) The SGLT-2 inhibitor will be rendered ineffective, because CYP3A4 is required to convert these agents from inactive prodrugs to their active forms
D) Renal clearance of the SGLT-2 inhibitor will rise substantially, because CYP3A4 inhibition upregulates tubular secretion of glucuronidated metabolites
E) Marked accumulation is expected because SGLT-2 inhibitors are eliminated unchanged by the kidney and CYP3A4 inhibition blocks their only route of elimination
ANSWER: A
Rationale:
The SGLT-2 inhibitor class is metabolized primarily by glucuronidation through UDP-glucuronosyltransferase (UGT) enzymes, with minimal cytochrome P450 (CYP450) involvement. Canagliflozin is glucuronidated by UGT1A9 and UGT2B4, dapagliflozin by UGT1A9, and empagliflozin predominantly by UGT enzymes, all with minimal CYP contribution. A strong CYP3A4 inhibitor would therefore be expected to produce minimal clinically significant change in SGLT-2 inhibitor exposure.
Option B: Option B is incorrect because the class is not predominantly CYP3A4-metabolized, so a large CYP-mediated exposure increase is not expected.
Option C: Option C is incorrect because these agents are active drugs, not CYP3A4-dependent prodrugs, so CYP inhibition would not render them ineffective.
Option D: Option D is incorrect because CYP3A4 inhibition does not upregulate tubular secretion of glucuronides, and renal clearance would not rise on this basis.
Option E: Option E is incorrect because, although a fraction is excreted, these agents are cleared substantially by glucuronidation rather than eliminated entirely unchanged by the kidney, and CYP3A4 is not their elimination route.
7. A clinician wants to apply a single estimated glomerular filtration rate (eGFR) cutoff below which "no SGLT-2 inhibitor should ever be started, for any reason." Why is this approach incorrect?
A) Because eGFR is irrelevant to SGLT-2 inhibitor use; these agents can be initiated at any level of renal function without dose or indication considerations
B) Because eGFR floors are both agent-specific and indication-specific: the threshold for the glycemic indication is generally higher (around 45 mL/min/1.73 m2) than the lower floors permitted for cardiovascular or renal indications with dapagliflozin and empagliflozin (roughly 20 to 25 mL/min/1.73 m2)
C) Because a single universal floor of 60 mL/min/1.73 m2 applies uniformly to every agent and every indication, which is higher than the value most clinicians assume
D) Because the eGFR floor depends only on the agent and never on the indication, so the correct approach is one fixed cutoff per drug regardless of why it is being used
E) Because the eGFR floor depends only on the indication and never on the agent, so the correct approach is one fixed cutoff per indication regardless of which drug is chosen
ANSWER: B
Rationale:
The eGFR threshold below which an SGLT-2 inhibitor should not be initiated varies by agent and by the indication being treated. For glycemic control, most agents require eGFR at or above approximately 45 mL/min/1.73 m2. For cardiovascular or renal indications, the floors are lower: dapagliflozin and empagliflozin may be used for heart failure or chronic kidney disease (CKD) indications down to roughly eGFR 20 to 25 mL/min/1.73 m2. A single universal floor therefore cannot be applied.
Option A: Option A is incorrect because eGFR is highly relevant; agent- and indication-specific floors exist precisely because renal function constrains use.
Option C: Option C is incorrect because there is no uniform 60 mL/min/1.73 m2 floor across all agents and indications; the floors are lower and variable.
Option D: Option D is incorrect because the floor is not agent-only; the same agent has different floors for glycemic versus cardiorenal indications.
Option E: Option E is incorrect because the floor is not indication-only; floors also differ across agents (for example, empagliflozin and dapagliflozin permit lower thresholds than ertugliflozin for non-glycemic use).
8. A 64-year-old patient has heart failure with reduced ejection fraction and chronic kidney disease with albuminuria but does NOT have type 2 diabetes mellitus and has a normal HbA1c. Which statement correctly describes SGLT-2 inhibitor eligibility?
A) The patient is ineligible for any SGLT-2 inhibitor because all approved indications for the class require a diagnosis of type 2 diabetes mellitus
B) The patient may be prescribed canagliflozin for the heart failure indication, since canagliflozin carries the broadest non-glycemic approvals of the class
C) Dapagliflozin or empagliflozin may be prescribed for the heart failure and chronic kidney disease indications regardless of type 2 diabetes mellitus status, with no glycemic indication or HbA1c threshold required
D) The patient must first be started on metformin to establish a glycemic indication before any SGLT-2 inhibitor can be added for cardiac or renal benefit
E) Only ertugliflozin is appropriate here, because it is the agent specifically approved for heart failure and chronic kidney disease in patients without diabetes
ANSWER: C
Rationale:
Dapagliflozin and empagliflozin are approved for heart failure (both reduced and preserved ejection fraction) and for chronic kidney disease (CKD) regardless of type 2 diabetes mellitus (T2DM) status. For a patient with heart failure or CKD but without T2DM, either agent can be prescribed for the cardiac or renal indication alone, with no glycemic indication and no HbA1c threshold requirement.
Option A: Option A is incorrect because the non-glycemic cardiorenal indications explicitly do not require a T2DM diagnosis.
Option B: Option B is incorrect because canagliflozin's non-glycemic approval is for diabetic kidney disease and requires T2DM; it does not carry the broad T2DM-independent heart failure approval that dapagliflozin and empagliflozin have.
Option D: Option D is incorrect because no glycemic indication or metformin prerequisite is needed to prescribe dapagliflozin or empagliflozin for the cardiorenal indications.
Option E: Option E is incorrect because ertugliflozin has no approved non-glycemic indications; dapagliflozin and empagliflozin are the agents approved for heart failure and CKD independent of diabetes.
9. In the EMPA-REG OUTCOME trial of empagliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease, the reduction in the primary three-point major adverse cardiovascular event (MACE) composite was statistically significant. Which finding best characterizes what drove that benefit?
A) The MACE reduction was driven almost entirely by large, statistically significant decreases in both non-fatal myocardial infarction and non-fatal stroke, consistent with rapid plaque regression
B) The MACE reduction was driven by a significant fall in non-fatal stroke specifically, mirroring the benefit pattern of glucagon-like peptide-1 receptor agonists
C) There was no significant change in any component; the composite reached significance only through a reduction in all-cause hospitalizations unrelated to cardiovascular events
D) The MACE reduction was driven almost entirely by a large reduction in cardiovascular death, with no significant difference in myocardial infarction or stroke rates, and heart failure hospitalization was also markedly reduced
E) The MACE reduction was driven by a decrease in non-fatal myocardial infarction alone, with cardiovascular death and stroke rates unchanged between groups
ANSWER: D
Rationale:
In EMPA-REG OUTCOME, empagliflozin reduced the primary three-point MACE composite by approximately 14% versus placebo, and that reduction was driven almost entirely by a large (roughly 38%) reduction in cardiovascular death; rates of myocardial infarction and stroke did not differ significantly between groups. Hospitalization for heart failure was also markedly reduced (about 35%), establishing the heart failure hospitalization signal that became the class signature. The rapidity of the mortality benefit was inconsistent with an atherosclerosis-slowing mechanism and instead pointed to a hemodynamic effect.
Option A: Option A is incorrect because myocardial infarction and stroke were not significantly reduced and plaque regression was not the mechanism.
Option B: Option B is incorrect because the stroke-driven benefit pattern characterizes glucagon-like peptide-1 receptor agonists, not empagliflozin in this trial.
Option C: Option C is incorrect because the composite reached significance through cardiovascular death reduction, not through nonspecific all-cause hospitalizations.
Option E: Option E is incorrect because the benefit was not driven by myocardial infarction reduction; cardiovascular death was the dominant component and myocardial infarction was not significantly changed.
10. The CANVAS program identified a safety signal that has shaped agent selection within the SGLT-2 inhibitor class. Which statement correctly describes this signal?
A) CANVAS demonstrated a class-wide doubling of pancreatitis risk that has since been confirmed for every SGLT-2 inhibitor in subsequent trials
B) CANVAS demonstrated a class-wide increase in hemorrhagic stroke that applies equally to dapagliflozin and empagliflozin
C) CANVAS showed a reduction in lower extremity amputations with canagliflozin, an unexpected protective signal later confirmed across the class
D) CANVAS identified an increase in major hypoglycemic events with canagliflozin, establishing hypoglycemia as the defining class risk
E) CANVAS identified an increased risk of lower extremity amputation with canagliflozin (hazard ratio approximately 1.97), a signal considered largely canagliflozin-specific that has not been consistently replicated across the class
ANSWER: E
Rationale:
The CANVAS program randomized patients with type 2 diabetes mellitus and either established cardiovascular disease or multiple risk factors to canagliflozin or placebo, reducing the primary three-point MACE composite by about 14%. It also identified two safety signals: an increased risk of lower extremity amputation (hazard ratio approximately 1.97, primarily toe amputations) and an increase in bone fractures. The amputation signal has not been consistently replicated across the class or even across all canagliflozin trials (CREDENCE showed no significant excess) and is considered largely canagliflozin-specific.
Option A: Option A is incorrect because CANVAS did not establish a class-wide confirmed doubling of pancreatitis risk.
Option B: Option B is incorrect because CANVAS did not demonstrate a class-wide hemorrhagic stroke increase applying to dapagliflozin and empagliflozin.
Option C: Option C is incorrect because the amputation finding was an increase, not a protective reduction, and it was not confirmed class-wide.
Option D: Option D is incorrect because the defining CANVAS safety signals were amputation and fracture, not major hypoglycemia; SGLT-2 inhibitors carry low intrinsic hypoglycemia risk because their mechanism is insulin-independent.
11. DECLARE-TIMI 58, the largest SGLT-2 inhibitor cardiovascular outcome trial, enrolled a population in which only about 40% had established atherosclerotic cardiovascular disease. Which result pattern did this trial demonstrate for dapagliflozin?
A) Dapagliflozin significantly reduced the primary three-point MACE composite, driven by a large reduction in non-fatal myocardial infarction
B) Dapagliflozin did not significantly reduce the primary three-point MACE composite (meeting non-inferiority for safety), but significantly reduced the secondary composite of cardiovascular death or heart failure hospitalization, with the heart failure hospitalization component driving that benefit
C) Dapagliflozin significantly increased MACE compared with placebo, failing even the non-inferiority criterion for cardiovascular safety
D) Dapagliflozin significantly reduced both MACE and heart failure hospitalization to an equal degree, with stroke reduction being the dominant contributor
E) Dapagliflozin showed no effect on any cardiovascular endpoint, including heart failure hospitalization, in the overall trial population
ANSWER: B
Rationale:
DECLARE-TIMI 58 enrolled over 17,000 patients, only about 40% with established atherosclerotic cardiovascular disease. Dapagliflozin did not significantly reduce the primary three-point MACE composite in the overall population (it met the cardiovascular safety non-inferiority criterion), but it produced a significant reduction in the pre-specified secondary composite of cardiovascular death or hospitalization for heart failure, with the heart failure hospitalization component driving the benefit. This divergence reinforced that SGLT-2 inhibitors act primarily through heart failure mechanisms rather than atherosclerosis modification.
Option A: Option A is incorrect because MACE was not significantly reduced and the benefit was not driven by myocardial infarction.
Option C: Option C is incorrect because dapagliflozin met the non-inferiority safety criterion and did not increase MACE.
Option D: Option D is incorrect because MACE was not significantly reduced and stroke was not the dominant contributor; heart failure hospitalization drove the secondary benefit.
Option E: Option E is incorrect because dapagliflozin did reduce heart failure hospitalization, so it was not without effect on cardiovascular endpoints.
12. A patient with type 2 diabetes mellitus has both established atherosclerotic cardiovascular disease and heart failure. In counseling about the complementary roles of an SGLT-2 inhibitor and a glucagon-like peptide-1 receptor (GLP-1R) agonist, which statement is correct?
A) SGLT-2 inhibitors reduce cardiovascular risk predominantly through a hemodynamic, heart-failure-oriented mechanism, whereas GLP-1R agonists reduce risk predominantly through an anti-atherosclerotic mechanism (notably stroke and MACE); the two classes are complementary and may be combined
B) Both classes act through identical anti-atherosclerotic mechanisms, so combining them provides no additional benefit over either drug alone
C) SGLT-2 inhibitors reduce atherosclerotic stroke while GLP-1R agonists reduce heart failure hospitalization, so the patient should receive only the GLP-1R agonist for the heart failure component
D) GLP-1R agonists reduce cardiovascular risk through volume unloading and preload reduction, while SGLT-2 inhibitors act by slowing atherosclerotic plaque progression
E) The two classes are pharmacodynamically antagonistic and should never be co-prescribed because their cardiovascular mechanisms cancel each other out
ANSWER: A
Rationale:
SGLT-2 inhibitor cardiovascular outcome trials show benefit driven by reduced heart failure hospitalization and cardiovascular death, consistent with a hemodynamic mechanism (volume unloading, preload and afterload reduction). GLP-1R agonist trials show benefit driven by reduction in atherosclerotic events, particularly stroke and MACE, consistent with an anti-atherosclerotic mechanism. When a patient has both established atherosclerotic disease and heart failure, both classes are indicated and are complementary, so they may be combined.
Option B: Option B is incorrect because the classes do not share identical mechanisms; their distinct mechanisms are precisely why combination adds benefit.
Option C: Option C is incorrect because it reverses the mechanisms: SGLT-2 inhibitors address heart failure and GLP-1R agonists address atherosclerotic stroke, so withholding the SGLT-2 inhibitor would forgo the heart failure benefit.
Option D: Option D is incorrect because it inverts the two mechanisms: volume unloading is the SGLT-2 inhibitor effect, and anti-atherosclerotic action is the GLP-1R agonist effect.
Option E: Option E is incorrect because the classes are complementary rather than antagonistic and are appropriately co-prescribed in this setting.
13. Heart failure with preserved ejection fraction (HFpEF) was historically resistant to pharmacologic therapies showing outcome benefit. Which trial result changed that landscape for the SGLT-2 inhibitor class?
A) DAPA-HF demonstrated that dapagliflozin was the first agent to show outcome benefit specifically in preserved ejection fraction heart failure
B) EMPA-REG OUTCOME established empagliflozin as the first agent with proven benefit in preserved ejection fraction heart failure, independent of its diabetes population
C) VERTIS-CV demonstrated ertugliflozin superiority in preserved ejection fraction heart failure, extending the class benefit to this population
D) EMPEROR-Preserved demonstrated that empagliflozin significantly reduced the primary composite of cardiovascular death or heart failure hospitalization in HFpEF, making it the first pharmacological agent to show superiority over placebo for this composite in preserved ejection fraction
E) CANVAS established canagliflozin as the first agent with outcome benefit in preserved ejection fraction heart failure, driven by a reduction in cardiovascular mortality
ANSWER: D
Rationale:
EMPEROR-Preserved enrolled patients with heart failure and a left ventricular ejection fraction above 40% and demonstrated that empagliflozin significantly reduced the primary composite of cardiovascular death or hospitalization for heart failure (approximately a 21% reduction), making empagliflozin the first pharmacological agent to demonstrate superiority over placebo for this composite in heart failure with preserved ejection fraction (HFpEF).
Option A: Option A is incorrect because DAPA-HF studied heart failure with reduced ejection fraction, not preserved ejection fraction.
Option B: Option B is incorrect because EMPA-REG OUTCOME was a cardiovascular outcome trial in type 2 diabetes with established atherosclerotic disease, not a dedicated preserved ejection fraction heart failure trial.
Option C: Option C is incorrect because VERTIS-CV did not establish ertugliflozin benefit in preserved ejection fraction heart failure; ertugliflozin lacks approved non-glycemic indications.
Option E: Option E is incorrect because CANVAS was a cardiovascular outcome trial in type 2 diabetes and did not establish canagliflozin as the first agent with preserved ejection fraction heart failure benefit.
14. Across the dedicated heart failure outcome trials of SGLT-2 inhibitors (such as the EMPEROR program), which component most consistently drives the benefit in the primary composite endpoint?
A) A large reduction in all-cause mortality, with heart failure hospitalization unchanged
B) A reduction in sudden cardiac death attributable to a direct antiarrhythmic membrane effect of the drug class
C) A reduction in heart failure hospitalizations (including recurrent events), rather than a reduction in cardiovascular mortality, that primarily drives the composite benefit
D) A reduction in myocardial infarction rates, reflecting an anti-atherosclerotic mechanism unique to the heart failure population
E) A reduction in ischemic stroke, paralleling the dominant benefit seen with glucagon-like peptide-1 receptor agonists
ANSWER: C
Rationale:
Consistent with the hemodynamic, heart-failure-oriented mechanism of SGLT-2 inhibitors, the benefit in the dedicated heart failure trials (including the EMPEROR program) is driven primarily by reduced heart failure hospitalizations, including recurrent events, rather than by a reduction in cardiovascular mortality.
Option A: Option A is incorrect because the dominant driver is reduced heart failure hospitalization, and the mortality benefit is more modest, not a large all-cause mortality reduction with hospitalizations unchanged.
Option B: Option B is incorrect because the class does not act through a direct antiarrhythmic membrane effect reducing sudden cardiac death as the driving mechanism.
Option D: Option D is incorrect because myocardial infarction reduction (an anti-atherosclerotic effect) is not the driver; SGLT-2 inhibitor benefit in heart failure is hemodynamic.
Option E: Option E is incorrect because ischemic stroke reduction is the GLP-1 receptor agonist benefit pattern, not the SGLT-2 inhibitor heart failure mechanism.
15. Several mechanisms have been proposed for the heart failure benefit of SGLT-2 inhibitors that are distinct from their glycemic effect. Which option best captures the proposed hemodynamic and metabolic contributions?
A) Heart failure benefit results from direct positive inotropy, increasing contractility through enhanced calcium-induced calcium release in the failing myocardium
B) Heart failure benefit results from aggressive loop-diuretic-like natriuresis that depends on strong activation of the renin-angiotensin and sympathetic systems to be effective
C) Heart failure benefit results from beta-adrenergic receptor blockade, slowing heart rate and reducing myocardial oxygen demand as the dominant mechanism
D) Heart failure benefit results from coronary vasodilation that increases myocardial oxygen delivery, independent of any change in volume status
E) Heart failure benefit involves preload reduction through osmotic diuresis and natriuresis (without the neurohormonal activation that typically accompanies aggressive diuresis), modest afterload reduction from blood pressure lowering, and a proposed metabolic shift toward ketone body (beta-hydroxybutyrate) oxidation as a more oxygen-efficient fuel for the failing heart
ANSWER: E
Rationale:
The proposed heart failure mechanisms of SGLT-2 inhibitors are distinct from glycemic lowering. They include preload reduction through osmotic diuresis and natriuresis and modest afterload reduction from blood pressure lowering, achieved without triggering the neurohormonal compensatory activation (renin-angiotensin and sympathetic) that usually accompanies aggressive diuresis, possibly because volume loss is gradual. Additional proposed mechanisms include reduced epicardial fat, anti-fibrotic effects, and a metabolic shift toward ketone body (beta-hydroxybutyrate) oxidation as a more oxygen-efficient fuel for the energy-depleted failing heart (the "thrifty substrate" hypothesis).
Option A: Option A is incorrect because the class does not act through direct positive inotropy via enhanced calcium-induced calcium release.
Option B: Option B is incorrect because the natriuresis is notable precisely for occurring without strong neurohormonal activation, unlike aggressive loop diuresis.
Option C: Option C is incorrect because beta-adrenergic blockade is not the SGLT-2 inhibitor mechanism.
Option D: Option D is incorrect because coronary vasodilation increasing oxygen delivery independent of volume status is not the proposed mechanism; volume unloading and the metabolic substrate shift are central.
16. CREDENCE was a dedicated renal outcome trial of canagliflozin in patients with type 2 diabetes mellitus and diabetic kidney disease receiving maximally tolerated RAAS blockade. Which statement best describes its result?
A) The trial ran its full planned duration and showed no significant effect on the primary renal composite, prompting withdrawal of canagliflozin's renal indication
B) The trial was stopped early for overwhelming efficacy, with canagliflozin reducing the primary renal composite (end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) by approximately 30%
C) The trial was stopped early for harm, driven by an excess of acute kidney injury and hyperkalemia in the canagliflozin arm
D) The trial showed renal benefit only in the subgroup without albuminuria, with no effect in patients with established proteinuria
E) The trial demonstrated a reduction in the primary renal composite that was entirely attributable to glycemic improvement, with no independent hemodynamic renoprotection
ANSWER: B
Rationale:
CREDENCE enrolled patients with type 2 diabetes mellitus and diabetic kidney disease (reduced eGFR with substantial albuminuria) on maximally tolerated renin-angiotensin-aldosterone system blockade, randomized to canagliflozin or placebo. It was stopped early at a median follow-up of about 2.6 years because of overwhelming efficacy: canagliflozin reduced the primary renal composite (end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) by approximately 30%.
Option A: Option A is incorrect because the trial did not run its full duration and did show a significant benefit, leading to a renal indication rather than withdrawal.
Option C: Option C is incorrect because the trial was stopped for efficacy, not harm; it was not driven by an acute kidney injury and hyperkalemia excess.
Option D: Option D is incorrect because the enrolled population had albuminuria and the benefit was demonstrated in that proteinuric population, not confined to a non-albuminuric subgroup.
Option E: Option E is incorrect because the renoprotection is mediated substantially through a hemodynamic (tubuloglomerular feedback) mechanism independent of glycemic improvement, not entirely attributable to glucose lowering.
17. DAPA-CKD and EMPA-KIDNEY extended the renal evidence base for SGLT-2 inhibitors beyond the diabetic population studied in CREDENCE. What key conclusion did these trials support?
A) Renal benefit is confined to patients with type 2 diabetes mellitus, because SGLT-2 inhibitors require hyperglycemia-driven glycosuria to protect the kidney
B) Renal benefit appears only in patients with eGFR above 60 mL/min/1.73 m2, so these agents should not be used once chronic kidney disease is established
C) Renal benefit was observed only when the agents were used without background RAAS blockade, indicating the two mechanisms are mutually exclusive
D) SGLT-2 inhibitors reduce adverse renal outcomes in chronic kidney disease regardless of type 2 diabetes mellitus status (DAPA-CKD enrolled a substantial proportion of patients without diabetes), and EMPA-KIDNEY further extended protection to lower eGFR ranges
E) Renal benefit was demonstrated only in patients without albuminuria, reversing the albuminuria-based enrollment rationale used in CREDENCE
ANSWER: D
Rationale:
DAPA-CKD enrolled patients with chronic kidney disease (CKD) regardless of type 2 diabetes mellitus (T2DM) status, with roughly a third of patients having no diabetes, and demonstrated a substantial reduction in the primary renal composite. EMPA-KIDNEY further extended renal protection to patients with CKD across a broad range including lower eGFR values. Together they established that the renoprotective benefit is independent of diabetes status.
Option A: Option A is incorrect because the benefit is not confined to T2DM; non-diabetic CKD patients also benefited, and the hemodynamic mechanism does not depend on hyperglycemia.
Option B: Option B is incorrect because benefit was shown in established CKD with reduced eGFR, not limited to eGFR above 60 mL/min/1.73 m2.
Option C: Option C is incorrect because patients were typically on background RAAS blockade, and the mechanisms are complementary rather than mutually exclusive.
Option E: Option E is incorrect because albuminuria was part of the enrollment and risk-enrichment rationale, and benefit was not restricted to non-albuminuric patients.
18. A patient with type 2 diabetes mellitus on an SGLT-2 inhibitor presents with nausea, vomiting, and malaise. The plasma glucose is 190 mg per deciliter. Which principle is most important in this scenario?
A) Diabetic ketoacidosis is effectively excluded by the near-normal glucose level, so ketone testing is unnecessary and evaluation can focus elsewhere
B) The SGLT-2 inhibitor should be doubled to improve glycemic control, since the modestly elevated glucose indicates undertreatment as the cause of symptoms
C) Euglycemic diabetic ketoacidosis must be considered: ketoacidosis can develop with glucose that is not markedly elevated (often below approximately 252 mg per deciliter), so serum or urine ketones should be measured regardless of the glucose level
D) Symptoms in this setting are almost always due to genital mycotic infection, which is the explanation that should be pursued first
E) The presentation reflects expected osmotic diuresis and requires only increased oral fluid intake without further metabolic workup
ANSWER: C
Rationale:
Euglycemic diabetic ketoacidosis (DKA) is the most serious metabolic complication of SGLT-2 inhibitor therapy and is dangerous precisely because ketoacidosis can develop without markedly elevated glucose, typically with glucose below about 14 millimoles per liter (252 mg per deciliter). The glycosuric effect prevents glucose accumulation while glucagon excess drives hepatic ketogenesis. Any patient on an SGLT-2 inhibitor presenting with nausea, vomiting, or malaise should have serum or urine ketones measured regardless of the glucose level.
Option A: Option A is incorrect because a near-normal glucose does not exclude euglycemic DKA; this is the central diagnostic pitfall.
Option B: Option B is incorrect because increasing the SGLT-2 inhibitor in a patient who may be developing euglycemic DKA is dangerous; the drug should be held and ketones checked.
Option D: Option D is incorrect because, although genital mycotic infection is the most common adverse effect, nausea and vomiting with malaise mandate evaluation for euglycemic DKA first.
Option E: Option E is incorrect because these symptoms warrant ketone measurement, not reassurance as benign osmotic diuresis.
19. A patient on an SGLT-2 inhibitor is scheduled for major elective surgery. What is the appropriate perioperative management of the SGLT-2 inhibitor?
A) Continue the SGLT-2 inhibitor through the day of surgery, since holding it risks rebound hyperglycemia that outweighs any perioperative concern
B) Discontinue the SGLT-2 inhibitor 3 to 4 days before planned major surgery and resume only after the patient is eating and drinking normally with normal (negative) ketones
C) Hold the SGLT-2 inhibitor only on the morning of surgery and restart it in the recovery room once the patient is hemodynamically stable
D) Switch the SGLT-2 inhibitor to a higher dose preoperatively to ensure adequate glycemic control during the fasting period
E) No change is needed because a normal preoperative glucose reliably excludes any risk of perioperative ketoacidosis
ANSWER: B
Rationale:
Because SGLT-2 inhibitors predispose to euglycemic diabetic ketoacidosis (DKA) during periods of relative insulin deficiency such as surgery and fasting, the perioperative protocol requires discontinuing them 3 to 4 days before planned major surgery and resuming only after the patient is eating and drinking normally with normal (negative) ketones and no ongoing infection.
Option A: Option A is incorrect because continuing the drug through surgery raises the risk of perioperative euglycemic DKA, which outweighs the rebound hyperglycemia concern.
Option C: Option C is incorrect because holding only on the morning of surgery is insufficient given the drug's pharmacodynamic persistence; a 3-to-4-day lead time is needed.
Option D: Option D is incorrect because increasing the dose preoperatively increases, rather than mitigates, euglycemic DKA risk during fasting.
Option E: Option E is incorrect because a normal preoperative glucose does not exclude euglycemic DKA, which is the key pitfall of this complication.
20. A patient on an SGLT-2 inhibitor presents with rapidly progressive perineal pain, swelling, and erythema with systemic toxicity. Fournier gangrene is suspected. What is the appropriate immediate management?
A) Discontinue the SGLT-2 inhibitor and obtain immediate surgical consultation, because Fournier gangrene (necrotizing fasciitis of the perineum and genitalia) carries high mortality without early surgical debridement
B) Continue the SGLT-2 inhibitor and treat empirically with a topical antifungal, since perineal symptoms in this population are almost always uncomplicated candidiasis
C) Continue the SGLT-2 inhibitor and arrange routine outpatient urology follow-up within several weeks, as the condition is typically indolent
D) Reduce the SGLT-2 inhibitor dose by half and observe for 48 hours before deciding whether intervention is warranted
E) Discontinue the SGLT-2 inhibitor but defer any surgical evaluation until blood cultures have finalized, since antibiotics alone are usually curative
ANSWER: A
Rationale:
Fournier gangrene is a rare but life-threatening necrotizing fasciitis of the perineum and genitalia associated with SGLT-2 inhibitor use; glucosuria in the perineal area is thought to create a nutrient-rich environment for polymicrobial growth. In any patient with suspected Fournier gangrene, the SGLT-2 inhibitor should be discontinued and immediate surgical consultation obtained, because mortality is high without early surgical debridement.
Option B: Option B is incorrect because treating presumptively as candidiasis and continuing the drug would dangerously delay surgical care in a necrotizing infection.
Option C: Option C is incorrect because the condition is fulminant, not indolent; routine outpatient follow-up would be inappropriate and dangerous.
Option D: Option D is incorrect because dose reduction and watchful observation delay definitive surgical management of a rapidly progressive infection.
Option E: Option E is incorrect because antibiotics alone are not curative; early surgical debridement is essential and should not await culture results.
21. Which adverse effect is the most common with SGLT-2 inhibitor therapy, and what is its underlying mechanism and usual management?
A) Hyperkalemia, caused by aldosterone suppression, typically requiring immediate drug discontinuation and emergent potassium-lowering therapy
B) Severe hypoglycemia, caused by excessive insulin secretion, usually requiring dose reduction of the SGLT-2 inhibitor
C) Acute pancreatitis, caused by a direct toxic effect on pancreatic acinar cells, requiring permanent discontinuation
D) Lactic acidosis, caused by impaired hepatic lactate clearance, requiring urgent hemodialysis in most cases
E) Genital mycotic infection (vulvovaginal candidiasis in women, balanitis in uncircumcised men), caused by glucosuria creating a favorable environment for Candida growth; most cases are mild to moderate, respond to standard antifungal treatment, and do not require drug discontinuation unless recurrent or severe
ANSWER: E
Rationale:
Genital mycotic infections are the most common adverse effect of SGLT-2 inhibitors, occurring in roughly 6 to 14% of women and 3 to 5% of men in trials. The mechanism is glucosuria creating a favorable environment for Candida species growth in the genital area. Most infections (vulvovaginal candidiasis in women, balanitis in uncircumcised men) are mild to moderate, respond to standard topical or oral antifungal treatment, and do not require drug discontinuation unless recurrent or severe.
Option A: Option A is incorrect because hyperkalemia from aldosterone suppression is not the characteristic or most common SGLT-2 inhibitor adverse effect.
Option B: Option B is incorrect because SGLT-2 inhibitors act through an insulin-independent mechanism and carry low intrinsic hypoglycemia risk; they do not cause severe hypoglycemia through excessive insulin secretion.
Option C: Option C is incorrect because acute pancreatitis from direct acinar toxicity is not the most common adverse effect of this class.
Option D: Option D is incorrect because lactic acidosis is associated with metformin in specific settings, not the characteristic common adverse effect of SGLT-2 inhibitors.
22. A patient with type 2 diabetes mellitus on insulin is being started on an SGLT-2 inhibitor, and the team is considering combination therapy options. Which statement correctly reflects SGLT-2 inhibitor combination principles?
A) Two different SGLT-2 inhibitors should be combined to maximize glycosuria, and the insulin dose should be increased at initiation to prevent loss of glycemic control
B) SGLT-2 inhibitors must never be combined with a glucagon-like peptide-1 receptor agonist because the two classes are pharmacodynamically antagonistic
C) SGLT-2 inhibitors cannot be used with metformin or sulfonylureas, limiting their role to monotherapy in most patients
D) SGLT-2 inhibitors should not be combined with one another, but may be combined with a glucagon-like peptide-1 receptor agonist (a complementary pairing), and when added to insulin the insulin dose is typically reduced by about 20% at initiation to limit hypoglycemia risk
E) SGLT-2 inhibitors require an increase in concurrent insulin dosing at initiation, because their insulin-independent mechanism markedly raises insulin requirements
ANSWER: D
Rationale:
SGLT-2 inhibitors should not be combined with each other. They may be combined with metformin, sulfonylureas (with attention to the sulfonylurea's hypoglycemia risk), dipeptidyl peptidase-4 inhibitors, insulin, and glucagon-like peptide-1 (GLP-1) receptor agonists. The SGLT-2 inhibitor plus GLP-1 receptor agonist pairing is pharmacodynamically complementary. When an SGLT-2 inhibitor is added to insulin, the insulin dose is typically reduced by approximately 20% at initiation to limit hypoglycemia risk.
Option A: Option A is incorrect because two SGLT-2 inhibitors should not be combined and insulin is reduced, not increased, at initiation.
Option B: Option B is incorrect because the SGLT-2 inhibitor and GLP-1 receptor agonist combination is complementary, not antagonistic, and is appropriately used together.
Option C: Option C is incorrect because SGLT-2 inhibitors can be combined with metformin and sulfonylureas; they are not restricted to monotherapy.
Option E: Option E is incorrect because the insulin dose is reduced (about 20%) rather than increased at initiation, given the added glucose-lowering effect and hypoglycemia risk.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.